Unfractionated heparin showed no clear difference in treatment cessation due to adverse events compared with low molecular weight heparin (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether unfractionated heparin changes thrombocytopenia compared with low molecular weight heparin (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether unfractionated heparin changes major bleeding compared with no pharmacological anticoagulation (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Citrate showed no clear difference in death at 28 days compared with unfractionated heparin (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Citrate probably leads to higher successful prevention of clotting compared with unfractionated heparin (moderate certainty).
Citrate showed no clear difference in treatment cessation due to adverse events compared with unfractionated heparin (low certainty).
Citrate showed no clear difference in recovery of kidney function compared with unfractionated heparin (low certainty).
Citrate showed no clear difference in thrombocytopenia compared with unfractionated heparin (low certainty).
The review found no eligible studies for this question.
Unfractionated heparin showed no clear difference in major bleeding compared with low molecular weight heparin (low certainty).
It is very uncertain whether unfractionated heparin changes death: unknown time frame compared with low molecular weight heparin (very low certainty).
The review found no eligible studies for this question.